Biovation Sciences Ltd is primarily working with research and experimental development within the field of biotechnology. Biovation has 1.590.000 shares and thus holds 29,95% of the total number of shares in QuickCool AB.

For additional information, please contact::
Fredrik Radencrantz, CEO
Phone: +46-46-286 38 40
E-mail: fredrik.radencrantz@quickcool.se

QuickCool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the QuickCool® SYSTEM. QuickCool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool’s solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool’s Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. QuickCool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to www.quickcool.se